Spermidine

TL;DR

Spermidine is a natural polyamine that induces autophagy via EP300 acetyltransferase inhibition. Preclinical lifespan extension is robust across species. However, oral spermidine at tested doses (≤40 mg/day) does not raise plasma spermidine levels in humans — it is presystemically converted to spermine. The strongest human evidence for health benefit comes from dietary intake (Bruneck, NHANES cohorts), not supplementation. SmartAge Phase 2b (n=100, 12 months) failed on its primary cognitive endpoint at 0.9 mg/day. Safety is adequate short-term (≤40 mg/day, ≤28 days); long-term data are absent. Cancer patients or those with cancer history should not supplement without explicit oncologist guidance.

Why it Matters for Vitals

• HRV and cardiovascular aging: Mouse data show ~20% reversal of aortic PWV (PMID:27841876); human cardiovascular response is extrapolated and investigational. If genuine, would manifest as improved arterial compliance → indirect HRV benefit via reduced afterload.
• Inflammation: Exploratory SmartAge signal showed slight CRP reduction; preclinical NF-κB inhibition is reported but not proven in humans.
• Sleep: Mechanistic plausibility for circadian normalization (Drosophila data); no direct human sleep architecture trial.
• Recovery/readiness: Autophagy induction is the theoretical basis, but no validated wearable signal for autophagy exists. Do not claim readiness improvement is attributable to spermidine.
• Glucose/body composition: No direct effect on glucose or body composition demonstrated in human trials.
• Key confound: Any biometric improvement in a spermidine-supplemented user is more likely attributable to the overall dietary pattern (Mediterranean-style eating) than to the supplement itself. Vitals coaching must not claim causal attribution.

Key Facts

Status	GRAS (wheat germ extract); NDI notification under review (spermidine HCl)
Class	Polyamine / Autophagy inducer / Obligatory downstream effector of fasting and rapamycin
Primary mechanism	EP300 acetyltransferase inhibition → autophagy via cytoplasmic acetyl-CoA competition; SIRT1-independent
Confirmed preclinical	Lifespan extension in yeast, C. elegans, Drosophila, mice; autophagy-dependent
Confirmed human PK	Oral 15 mg/day for 5 days → NO plasma spermidine elevation; presystemic conversion to spermine (PMID:37111071)
Confirmed human PK	Oral 40 mg/day for 28 days → minimal circulating polyamine effects (PMID:39405978)
Cognitive trial (Phase 2b)	SmartAge n=100, 12 months, 0.9 mg/day → primary endpoint NULL (P=0.47) (PMID:35616942)
Dose range tested	0.9–40 mg/day; no human trial beyond 12 months
Safety short-term	Adequate; NOAEL in mice >728 mg/kg/day; ~1,000–10,000× safety margin at typical doses
Key risk	Active or history of cancer: contraindicated (polyamine growth factor risk via eIF5A2); pregnancy/lactation: no safety data
Key trials pending	POLYCAD (24 mg/day, CAD, results Aug 2026); REPROGRAM (15 mg/day, senescent cell reduction, preprint 2026)

Mechanism Summary

EP300 acetyltransferase inhibition (primary — confirmed in human cells): Spermidine competes with acetyl-CoA at the EP300/p300 active site. EP300 normally acetylates and represses autophagy proteins (BECLIN1, LC3, ATG proteins). Direct binding of spermidine to BECLIN1 and LC3 demonstrated in human chondrocytes (PMID:30232322). Cytoplasmic mechanism confirmed — works in enucleated cells.

TFEB nuclear translocation: EP300 inhibition → mTORC1 suppression (indirect via AMPK in some tissues) → TFEB dephosphorylation → nuclear translocation → transcriptional autophagy-lysosomal program (CLEAR motifs).

eIF5A hypusination: Spermidine is the sole substrate for hypusination of translation factor eIF5A. Hypusinated eIF5A is required for efficient translation of autophagy genes. This is the key distinction from resveratrol: spermidine is NAD+-independent.

Obligatory effector of fasting and rapamycin (confirmed, PMID:39194297): Endogenous spermidine synthesis rises during fasting in yeast, flies, mice, and humans (4 independent clinical cohorts). Genetic blockade of spermidine synthesis abolishes fasting-mediated autophagy and longevity extension. Exogenous spermidine restores autophagy when synthesis is blocked. This positions spermidine as the downstream effector node for both caloric restriction and rapamycin — not merely a mimetic, but an obligatory component of the pathway.

Secondary mechanisms (Supported B or Reported C):

• Mitophagy via PINK1-Parkin pathway (PMID:27841876)
• SIRT1/PGC-1α mitochondrial biogenesis (PMID:31907336)
• NF-κB anti-inflammatory (PMID:34881079)
• eNOS up-regulation → arterial compliance (PMCID:PMC5411858)

What the Current Evidence Suggests

Strongest signal: dietary polyamine intake and mortality

Two independent prospective cohorts show association between dietary spermidine intake and reduced all-cause/CVD mortality:

• Bruneck Study (n=829, 20-year follow-up): HR=0.74 per 1-SD; fully adjusted HR=0.76. Top vs. bottom tertile ≈ 5.7 years younger biological age (post-hoc reification of a continuous risk metric).
• NHANES 2003–2014 (n=23,894): CVD mortality HR=0.68; all-cause mortality HR=0.70.

Critical caveat: Both cohorts reflect dietary intake from whole foods as part of Mediterranean-style dietary patterns — not isolated supplement use.

Cognitive function: null Phase 2b

• Phase 2a pilot (n=30, 3 months): Cohen’s d=0.77 for memory improvement (wide CIs, hypothesis-generating)
• Phase 2b (n=100, 12 months, 0.9 mg/day, pre-registered): treatment effect −0.03 (95% CI: −0.11 to 0.05), P=0.47 — NULL on primary endpoint. Exploratory signals in verbal memory and inflammation require replication.

Cardiovascular: ongoing trials

• POLYCAD (NCT06186102): 24 mg/day, 48 weeks, n=187 CAD patients. CMR LV mass, peak VO₂, DXA lean mass, hs-CRP. Results expected August 2026.
• REPROGRAM (ISRCTN47919839): 15 mg/day, senescent cell reduction endpoint. Preprint March 2026.

Safety: adequate short-term

• 0.9 mg/day × 12 months: no serious AEs, balanced vs. placebo
• 40 mg/day × 28 days: safe, minimal polyamine effects
• GLP 90-day mouse toxicology: NOAEL >728 mg/kg/day

Likely Wearable / Vitals Relevance

Signal	Direction	Evidence Grade	Vitals Note
HRV	Possibly improved	C (extrapolated from mouse cardiac data)	Not directly attributable to spermidine; flag investigational
Arterial stiffness (PWV proxy)	Possibly reduced	C (mouse data only)	No human PWV RCT; investigational
hs-CRP	Possibly reduced	B (exploratory SmartAge)	Lab work required; not wearable-derived
IL-6	Possibly reduced	C (preclinical NF-κB)	No direct human IL-6 RCT
Autophagy activity	Cannot be measured	—	No validated consumer wearable signal exists
Epigenetic age	Unknown	Gap	No trial has demonstrated epigenetic clock reversal

Risks and Uncertainty

Cancer risk (contested)

• Elevated polyamines consistently found in breast, colon, lung, prostate, and skin cancers; tumor cells release spermidine to suppress T-cell activation
• 2026 J Biol Chem (Tokyo University): polyamines promote cancer cell growth via eIF5A2 (distinct from eIF5A1 anti-aging effect in normal tissue)
• SAKE cohort: higher dietary spermidine intake associated with reduced cancer mortality — but this reflects food matrix and overall dietary pattern
• Resolution: Polyamines may prevent cancer initiation via autophagy/immune surveillance in healthy tissue while supporting growth of already-established tumors
• Vitals position: Active malignancy or cancer history = do not supplement without explicit oncologist approval

PK constraint

Oral spermidine does not reliably raise plasma spermidine at any dose tested up to 40 mg/day. The mechanistic claim (supplement → systemic autophagy induction) is disconnected from the route of administration used in all human trials.

Long-term safety gap

No human clinical trial data for spermidine supplementation beyond 12 months.

Supplement quality

• At least one FDA recall (April 2025) for undeclared wheat allergen in a commercial spermidine product
• Analytical survey: 34% of branded supplements exceeded biogenic amine safety limits
• No FDA-approved spermidine supplement exists; GMP compliance is variable

Drug interactions

• DFMO (irreversible ODC inhibitor): theoretical counteraction — do not co-advise
• Aspirin/NSAIDs: both inhibit EP300; additive GI bleeding risk
• Immunosuppressants/chemotherapy: no human data — gap

Best Stack Context

• Spermidine + Urolithin A: Dual general autophagy + targeted mitophagy; complementary clearance pathways
• Spermidine + Rapamycin: Rapamycin lifts mTOR blockade on ODC1 (endogenous spermidine synthesis); spermidine provides the downstream effector for autophagy; rapamycin’s longevity extension is entirely dependent on endogenous spermidine (PMID:39194297)
• Spermidine + NMN/NAD+: Independent axes; autophagy + NAD+/sirtuin are complementary, not redundant
• NOT with: Active cancer, cancer history, DFMO use, pregnancy/lactation

What Stays Inside This Hub

• Full regulatory landscape (FDA GRAS, EU Novel Food, CJEU ruling, EFSA claim rejection)
• Detailed PK tables from Schwarz 2023 and Keohane 2024
• Trial-by-trial evidence grades and status
• Aspirational links to the two pending high-impact trials (POLYCAD, REPROGRAM)

Related Notes

• Autophagy — general autophagy mechanism; Spermidine drives EP300-inhibition pathway; shared with Rapamycin, Urolithin A, Metformin
• Mitophagy — PINK1/Parkin pathway; Spermidine activates mitophagy (PMID:27841876); shared with Urolithin A, Rapamycin
• Rapamycin — complementary mTOR axis; Spermidine is the obligatory downstream effector of rapamycin’s longevity mechanism
• Urolithin A — mitophagy-specific; complementary to Spermidine’s broader autophagy induction
• NMN NAD+ — independent longevity axis; complementary to Spermidine
• Adaptogens MOC — Spermidine listed under adaptogens
• Vitals Knowledge Map — compound index

---

Evidence frontier: April 2026 | Batch 113 | Key refs: PMID:37111071, PMID:39405978, PMID:35616942, PMID:29955838, PMID:39194297